NANETS Symposium | Conference

XmAb18087 Shows Encouraging Preliminary Activity in NETs

October 3rd 2020

XmAb18087 demonstrated a disease control rate of 43% across dose levels in patients with neuroendocrine tumors and a favorable safety profile.

Novel Somatostatin Analog Shows Early Activity in Metastatic NETs, Irrespective of Primary Tumor Site

October 3rd 2020

The novel somatostatin analog for the Targeted Alpha-emitter Therapy 212Pb-DOTAMTATE has demonstrated early efficacy and a tolerable safety profile in a small cohort of patients with metastatic somatostatin receptor–expressing neuroendocrine tumors irrespective of location of the primary tumor.

Dr. Chauhan on Key Recent Advances in Neuroendocrine Tumors

October 3rd 2020

Aman Chauhan, MD, a medical oncologist at the University of Kentucky, discusses key recent advances in therapeutics for patients with neuroendocrine tumors, and points to the future with ongoing combination studies.

Increased Lanreotride Autogel Dosing Shows Encouraging Antitumor Activity in Progressive Pancreatic, Midguts NETs

October 3rd 2020

Increasing the dosage of lanreotide autogel from every 28 days to every 14 days led to encouraging progression-free survival outcomes in patients with progressive pancreatic and midgut neuroendocrine tumors.

Dr. Strosberg on Retreatment With Lutathera in Advanced NETs

October 3rd 2020

Jonathan Strosberg, MD, discusse​s retreatment with Lutathera in advanced neuroendocrine tumors.

Dr. Chauhan on the Role of Lutathera in NETs

October 3rd 2020

Aman Chauhan, MD, a medical oncologist at the University of Kentucky, discusses the role of ​Lutathera in neuroendocrine tumors.

Dual CDK4/6, MEK Blockade Demonstrates Synergy in PNET Models

October 2nd 2020

Combination CDK4/6 and MEK inhibition was “highly synergistic” in killing pancreatic neuroendocrine tumor cells in vitro and effectively suppressed PNET growth in mice.

Dr. Pavel on the PFS With Lanreotide Autogel in the CLARINET FORTE Trial

October 2nd 2020

Marianne Pavel, MD, discusses the progression-free survival of patients with pancreatic and midgut neuroendocrine tumors who are treated with lanreotide autogel in the phase 2 CLARINET FORTE trial.

Lutathera-Based PRRT Retreatment Shows OS Benefit With Acceptable Safety in NETs

October 2nd 2020

Retreatment with Lutathera-based peptide receptor radionuclide therapy has been shown to have an encouraging survival benefit with an acceptable safety in patients with neuroendocrine tumors.

Dr. Wolin on the Safety of Lutathera in Advanced NETs

October 2nd 2020

Edward Wolin, MD, discusses the safety profile of 177Lu-dotatate in patients with advanced neuroendocrine tumors.

Telotristat/Lutathera Combo Could Improve Outcomes in Well-Differentiated NETs

October 2nd 2020

Investigators are evaluating the combination of telotristat ethyl and Lutathera with a goal to improve progression-free survival in patients with well-differentiated neuroendocrine tumors in a randomized, phase 2 study that was highlighted during the 2020 NANETs Virtual Symposium.

Long-Term Toxicity Data Confirm the Tolerability of Lutathera in NETs

October 2nd 2020

Longer-term data demonstrated that treatment with the radiopharmaceutical Lutathera continued to show low rates of toxicity among patients with somatostatin receptor–positive neuroendocrine tumors.

Dr. Krampitz on Therapeutic Targets in pNETs

January 21st 2016

Geoffrey Krampitz, MD, Department of Stem Cell Biology and Regenerative Medicine, Stanford School of Medicine, identifies tumorigenic cells and therapeutic targets in patients with pancreatic neuroendocrine tumors.

Dr. Kunz on Potential of Immunotherapy in Neuroendocrine Tumors

October 17th 2015

Pamela L. Kunz, MD, assistant professor of Medicine (Oncology), Stanford University School of Medicine, discusses the potential of immunotherapy in the treatment of patients with neuroendocrine tumors (NETs).

Everolimus Shows Robust Activity in Lung/GI NETs

October 17th 2015

Everolimus improved progression-free survival by 7.1 months compared with placebo in patients with lung/gastrointestinal (GI) neuroendocrine tumors, representing a 52% reduction in the risk of progression or death.

Lu-Dotatate Shows Unprecedented PFS in Midgut NETs

October 17th 2015

Lu-Dotatate demonstrated an unprecedented 79% reduction in the risk of progression or death compared with high-dose octreotide LAR in patients with progressive, metastatic midgut neuroendocrine tumors.

Dr. Yao on the RADIANT-4 Study for NETs of Lung or GI Origin

October 17th 2015

James C. Yao, MD, professor, Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses results of the RADIANT-4 study, which examined the safety and efficacy of everolimus in advanced nonfunctional neuroendocrine tumors (NETs) of lung or gastrointestinal origin.

Dr. Anthony on Treatment Benefit With Telotristat Epitrate in Patients With Carcinoid Syndrome

October 16th 2015

Lowell B. Anthony, MD, professor of Medicine, University of Kentucky, discusses patient exit interviews from the phase III placebo-controlled TELESTAR trial, which evaluated telotristate epitrate in patients with inadequately controlled carcinoid syndrome.

Novel Drug Relieves Carcinoid Syndrome Symptoms

October 16th 2015

Telotristat etiprate, a novel serotonin synthesis inhibitor, helped reduce daily bowel movements for patients with carcinoid syndrome no longer responding to standard-of-care therapies.

Combining Chemo With mTOR Inhibitors Shows Promise in pNETS

October 16th 2015

Combining the chemotherapy streptozotocin with drugs that target the mTOR pathway may be an effective way to treat pancreatic neuroendocrine tumors.